In drug delivery to cancer tissues, conjugation of biomarkers are recently introduced? But, biomarker may suffered some changes in the body? My questions are these: First, what are the biological factors that decrease the delivery potentials of biomarkers? Second, how to protect biomarkers conjugated to nanodrugs form these biological  barriers?

More Hasan Kariminezhad's questions See All
Similar questions and discussions